Cargando…

Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient

BACKGROUND: Antisense oligonucleotide-induced exon skipping is a promising approach for treatment of Duchenne muscular dystrophy (DMD). We have systemically administered an antisense phosphorodiamidate morpholino oligomer (PMO) targeting dystrophin exons 6 and 8 to a dog with canine X-linked muscula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Takashi, Nakamura, Akinori, Aoki, Yoshitsugu, Yokota, Toshifumi, Okada, Takashi, Osawa, Makiko, Takeda, Shin'ichi
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923599/ https://www.ncbi.nlm.nih.gov/pubmed/20805873 http://dx.doi.org/10.1371/journal.pone.0012239

Ejemplares similares

Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts
por: Lee, Joshua, et al.
Publicado: (2018)

Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot
por: Suzuki, Hitoshi, et al.
Publicado: (2016)

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
por: Miskew Nichols, Bailey, et al.
Publicado: (2016)

Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle
por: Miyatake, Shouta, et al.
Publicado: (2019)

Skipping Multiple Exons to Treat DMD—Promises and Challenges
por: Aslesh, Tejal, et al.
Publicado: (2018)

Ensemble-Learning and Feature Selection Techniques for Enhanced Antisense Oligonucleotide Efficacy Prediction in Exon Skipping
por: Zhu, Alex, et al.
Publicado: (2023)

A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis
por: Anwar, Saeed, et al.
Publicado: (2021)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
por: Betts, Corinne, et al.
Publicado: (2012)

Exon 44 skipping in Duchenne muscular dystrophy: NS-089/NCNP-02, a dual-targeting antisense oligonucleotide
por: Watanabe, Naoki, et al.
Publicado: (2023)

Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012)

Systemic deletion of DMD exon 51 rescues clinically severe Duchenne muscular dystrophy in a pig model lacking DMD exon 52
por: Stirm, Michael, et al.
Publicado: (2023)

Dystrophinopathy Phenotypes and Modifying Factors in DMD Exon 45–55 Deletion
por: Poyatos‐García, Javier, et al.
Publicado: (2022)

In-Frame Deletion of Dystrophin Exons 8–50 Results in DMD Phenotype
por: Egorova, Tatiana V., et al.
Publicado: (2023)

Novel Exon-Skipping Therapeutic Approach for the DMD Gene Based on Asymptomatic Deletions of Exon 49
por: Abaji, Mario, et al.
Publicado: (2022)

Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013)

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice
por: Betts, Corinne A., et al.
Publicado: (2015)

Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan
por: Kuraoka, Mutsuki, et al.
Publicado: (2021)

A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20
por: Mata López, Sara, et al.
Publicado: (2018)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
por: Goossens, Remko, et al.
Publicado: (2023)

Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene
por: TAGLIA, ANTONELLA, et al.
Publicado: (2015)

Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse
por: Wang, Derek W., et al.
Publicado: (2018)

Becker muscular dystrophy caused by exon 2-truncating mutation of DMD
por: Ikeda, Tetsuhiko, et al.
Publicado: (2019)

Prevention of early-onset cardiomyopathy in Dmd exon 52–54 deletion mice by CRISPR-Cas9-mediated exon skipping
por: Rok, Matthew, et al.
Publicado: (2023)

Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention
por: Tyagi, Rahul, et al.
Publicado: (2019)

Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
por: Tanganyika-de Winter, Christa L, et al.
Publicado: (2012)

Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy
por: Lee, Joshua J.A., et al.
Publicado: (2018)

The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice
por: Hightower, Rylie M., et al.
Publicado: (2020)

Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides
por: Tone, Yuichiro, et al.
Publicado: (2021)

Mutation Types and Aging Differently Affect Revertant Fiber Expansion in Dystrophic Mdx and Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2013)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Targeting RyR Activity Boosts Antisense Exon 44 and 45 Skipping in Human DMD Skeletal or Cardiac Muscle Culture Models
por: Barthélémy, Florian, et al.
Publicado: (2019)

eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping
por: Chiba, Shuntaro, et al.
Publicado: (2021)

Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model
por: Sheng, Lei, et al.
Publicado: (2020)

NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
por: Watanabe, Naoki, et al.
Publicado: (2018)

Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2015)

Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs
por: Kuraoka, Mutsuki, et al.
Publicado: (2018)

Prime editing strategies to mediate exon skipping in DMD gene
por: Happi Mbakam, Cedric, et al.
Publicado: (2023)

Efficacy of exon-skipping therapy for DMD cardiomyopathy with mutations in actin binding domain 1
por: Shiba, Naoko, et al.
Publicado: (2023)

Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression
por: Ohtsuka, Yoshihisa, et al.
Publicado: (2015)

Mechanism of Deletion Removing All Dystrophin Exons in a Canine Model for DMD Implicates Concerted Evolution of X Chromosome Pseudogenes
por: VanBelzen, D. Jake, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s750se9nt8qjqbqt3c3re75c0a